Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.010% for Atopic Keratoconjunctivitis
NCT00884585Phase 3Completed
- Sponsor
- Allergan
- Start
- May 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of cyclosporine 2% ophthalmic solution in atopic keratoconjunctivitis (AKC), sponsored by Allergan. Started May 2009; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
atopic keratoconjunctivitis (AKC)
Beyond the preview
Go deeper on NCT00884585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884585.